Drug Trial Radar · NCT06079190
Efficacy and Safety of GSK4527226 [AL101] in Participants With Early Alzheimer's Disease
Last checked: Nov 20, 2026Latest source record: Sep 17, 2026 (this record)Source: ClinicalTrials.govMethods & limitations
Status
Terminated
Enrollment
367
Actual
Start
Oct 20, 2023
Primary completion
May 14, 2026
Study completion Aug 18, 2026
Sponsor
- Lead sponsor
- GlaxoSmithKlineGSK (GSK)
- Sponsor type
- Industry
- Collaborators
- Alector Inc.
- First posted
- Oct 12, 2023
Design
- Study type
- Interventional
- Phase
- Phase 2
- Allocation
- Randomized
- Model
- Parallel
- Masking
- Quadruple (participant, care provider, investigator, outcomes assessor)
- Primary purpose
- Treatment
- FDA-regulated drug
- Yes
- Who can join
- All sexes, from 50 years, up to 85 years
- Healthy volunteers
- No
Summary
As written by the sponsor on the registry.
The aim of this study is to assess the efficacy and safety of GSK4527226 in participants with early Alzheimer's Disease (AD) (including mild cognitive impairment \[MCI\] and mild dementia due to AD) of 2 dose levels of GSK4527226 compared to placebo.
Conditions
- Alzheimer's Disease
Interventions
GSK4527226Drug
GSK4527226 will be administered.
PlaceboOther
Placebo will be administered.
Primary outcomes
What the sponsor says the trial is designed to measure.
- Change from Baseline in Clinical Dementia Rating - Sum of Boxes (CDR-SB) Score for Dose 1 vs Placebo Across Weeks 52, 64 and 76Time frame: Baseline, Week 52, 64 and 76
Locations
97 sites in 16 countries. Site status is shown where the registry gives one.
GSK Investigational Site
San Diego, California
GSK Investigational Site
Lake Mary, Florida
GSK Investigational Site
Lake Worth, Florida
GSK Investigational Site
Maitland, Florida
GSK Investigational Site
Miami, Florida
GSK Investigational Site
Orlando, Florida
GSK Investigational Site
Orlando, Florida
GSK Investigational Site
Stuart, Florida
GSK Investigational Site
The Villages, Florida
GSK Investigational Site
The Villages, Florida
GSK Investigational Site
Decatur, Georgia
GSK Investigational Site
Elk Grove Village, Illinois
GSK Investigational Site
Chesterfield, Missouri
GSK Investigational Site
Toms River, New Jersey
GSK Investigational Site
Staten Island, New York
GSK Investigational Site
Matthews, North Carolina
GSK Investigational Site
North Canton, Ohio
GSK Investigational Site
Oklahoma City, Oklahoma
GSK Investigational Site
Portland, Oregon
GSK Investigational Site
Houston, Texas
GSK Investigational Site
Fairfax, Virginia
GSK Investigational Site
Buenos Aires, Argentina
GSK Investigational Site
Buenos Aires, Argentina
GSK Investigational Site
Ciudad Autonoma de Bueno, Argentina
GSK Investigational Site
Ciudad Autonoma de Buenos Aire, Argentina
GSK Investigational Site
Melbourne, Australia
GSK Investigational Site
Camperdown, New South Wales, Australia
GSK Investigational Site
Darlinghurst, New South Wales, Australia
GSK Investigational Site
Kogarah, New South Wales, Australia
GSK Investigational Site
Macquarie Park, New South Wales, Australia
GSK Investigational Site
Gold Coast, Queensland, Australia
GSK Investigational Site
Heidelberg, Victoria, Australia
GSK Investigational Site
Nedlands, Western Australia, Australia
GSK Investigational Site
Ottawa, Ontario, Canada
GSK Investigational Site
Peterborough, Ontario, Canada
GSK Investigational Site
Toronto, Ontario, Canada
GSK Investigational Site
Greenfield Park, Quebec, Canada
GSK Investigational Site
Sherbrooke, Quebec, Canada
GSK Investigational Site
Helsinki, Finland
GSK Investigational Site
Kuopio, Finland
Showing 40 of 97 sites, US sites first. The full list is on the registry record.
Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.
For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.